Trials / Recruiting
RecruitingNCT06431269
Feasibility and Efficiency of Screening for Neurodevelopmental Disorders by an Advanced Practice Nurse in Children With Congenital Heart Disease
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 1 Year – 5 Years
- Healthy volunteers
- Not accepted
Summary
Feasibility and efficiency of Screening for Neurodevelopmental Disorders by an Advanced Practice Nurse in Children aged 1 to 5 with Congenital Heart Disease
Detailed description
Congenital heart disease (CHD) is the leading cause of birth defects. Over 90% of children born with CHD reach adulthood. 50% of them will develop a neurodevelopmental disorder (NDD) that could affect life and long-term prognosis, including scholar and social integration and health related quality of life. In France, there is a lack of medical resources to screen NDD in this population and to refer patients for appropriate and early treatment. Investigators plan to propose a systematic early screening of NDD by an Advanced Practice Nurse (APN) during the usual cardiac follow-up. Children with CHD aged 1 to 5 will be included. If NDD is suspected, the patient will be referred to a neuropsychologist for NDD diagnosis confirmation and management planning. Patients with higher NDD risks (neonatal cardiac surgery) will benefit from a systematic neuropsychologist evaluation. This study will investigate the feasibility and performance of an APN screening in this NDD-high risk population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Screening for neurodevelopmental disorders by an advanced practice nurse | Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale |
Timeline
- Start date
- 2024-05-31
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2024-05-28
- Last updated
- 2025-09-25
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06431269. Inclusion in this directory is not an endorsement.